Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-15 5:30 pm Purchase | 2022-11-29 | 13G | Harvard Bioscience, Inc. HBIO | 272 Capital LP | 3,264,796 7.840% | 3,264,796 (New Position) | Filing History |
| 2023-02-14 4:05 pm Purchase | 2022-12-31 | 13G | Harvard Bioscience, Inc. HBIO | HARVEY PARTNERS, LLC | 2,911,500 7.000% | 2,911,500 (New Position) | Filing History |
| 2023-02-13 5:12 pm Purchase | 2022-12-31 | 13G | Harvard Bioscience, Inc. HBIO | Punch & Associates Investment Management, Inc. | 2,764,039 6.640% | 597,264 (+27.56%) | Filing History |
| 2023-02-13 3:55 pm Sale | 2022-12-31 | 13G | Harvard Bioscience, Inc. HBIO | Portolan Capital Management, LLC | 1,054,300 2.530% | -1,484,499 (-58.47%) | Filing History |
| 2023-01-11 1:30 pm Sale | 2023-01-06 | 13G | Harvard Bioscience, Inc. HBIO | Leviticus Partners LP | 2,053,907 4.930% | -200,000 (-8.87%) | Filing History |
| 2022-12-21 4:20 pm Purchase | 2022-12-16 | 13G | Harvard Bioscience, Inc. HBIO | Leviticus Partners LP | 2,253,907 5.410% | 2,253,907 (New Position) | Filing History |
| 2022-07-08 4:57 pm Sale | 2022-06-30 | 13G | Harvard Bioscience, Inc. HBIO | BlackRock Inc. BLK | 1,209,119 2.900% | -1,854,071 (-60.53%) | Filing History |
| 2022-06-21 4:01 pm Purchase | 2022-06-10 | 13G | HARVARD APPARATUS REGENERATIVE HRGN | HARVARD BIOSCIENCE INC HBIO | 708,516 5.800% | 708,516 (New Position) | Filing History |
| 2022-02-14 11:02 am Purchase | 2021-12-31 | 13G | Harvard Bioscience, Inc. HBIO | Punch & Associates Investment Management, Inc. | 2,166,775 5.310% | 2,166,775 (New Position) | Filing History |
| 2022-02-11 2:01 pm Purchase | 2021-12-31 | 13G | Harvard Bioscience, Inc. HBIO | Portolan Capital Management, LLC | 2,538,799 6.220% | 473,154 (+22.91%) | Filing History |
| 2022-02-08 3:52 pm Sale | 2022-02-14 | 13G | Harvard Bioscience, Inc. HBIO | Dimensional Fund Advisors LP | 1,883,598 4.600% | -143,393 (-7.07%) | Filing History |
| 2022-02-02 7:11 pm Purchase | 2021-12-31 | 13G | Harvard Bioscience, Inc. HBIO | BlackRock Inc. BLK | 3,063,190 7.500% | 109,285 (+3.70%) | Filing History |
| 2021-09-03 2:37 pm Purchase | 2021-08-24 | 13G | Harvard Bioscience, Inc. HBIO | Portolan Capital Management, LLC | 2,065,645 5.070% | 2,065,645 (New Position) | Filing History |
| 2021-02-16 3:14 pm Sale | 2020-12-31 | 13G | Harvard Bioscience, Inc. HBIO | Potomac Capital Management Inc. | 4,500 0.010% | -2,082,901 (-99.78%) | Filing History |
| 2021-02-12 5:13 pm Sale | 2021-02-16 | 13G | Harvard Bioscience, Inc. HBIO | Dimensional Fund Advisors LP | 2,026,991 5.200% | -105,805 (-4.96%) | Filing History |
| 2021-02-02 2:56 pm Purchase | 2020-12-31 | 13G | Harvard Bioscience, Inc. HBIO | BlackRock Inc. BLK | 2,953,905 7.600% | 1,505,228 (+103.90%) | Filing History |